Glioma patient-reported outcome assessment in clinical care

We congratulate Terri Armstrong and colleagues 1 Armstrong TS Dirven L Arons D et al. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 2020; 21: e97-103 Summary Full Text Full Text PDF PubMed Scopus (23) Google Scholar on their publication concerning glioma patient-reported outcome assessment in clinical care and research. We strongly agree with the perceived need to track symptoms and function that can potentially inform clinicians and investigators about whether standard and investigational treatments provide measurable benefits or adverse effects for patients. Care should be given to evoke additional aspects, which might further divulge, in our opinion, relevant patient insights and further perspectives. Glioma patient-reported outcome assessment in clinical care – Authors' replyWe thank Constantin Tuleasca and colleagues for their correspondence related to our Policy Review.1 We agree that there are many symptom, functional, and psychosocial effects that can be important to patients with glioma. We have proposed the quantitative, accurate, and sensitive measurement of a core set of symptoms and functional effects that are most directly related to disease and treatment symptomatology. The usefulness of having a core standardised brief assessment, particularly in a clinical trial context, cannot be overstated. Full-Text PDF Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportClinical trials of treatments for high-grade gliomas have traditionally relied on measures of response or time-dependent metrics; however, these endpoints have limitations because they do not characterise the functional or symptomatic effect of the condition on the person. Including clinical outcome assessments, such as patient- reported outcomes (PROs), to determine net clinical benefit of a treatment strategy is needed because of the substantial burden of symptoms and impaired functioning in this patient population. Full-Text PDF